On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when ...

SAN DIEGO--(BUSINESS WIRE)--Trestle Biotherapeutics, Inc., today announced a research collaboration with Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing ...

BRISBANE, Calif. and EDEN PRAIRIE, Minn., April 05, 2023 (GLOBE NEWSWIRE) -- CareDx, Inc. (CDNA) and Miromatrix Medical Inc. (MIRO) -- today announced an exclusive partnership aimed at advancing the ...

The FDA granted a Priority Review in February 2024 and was assigned a PDUFA date of August 10, 2024. ATEV is a bioengineered human tissue designed to be a universally implantable vascular conduit for ...

Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) - - After up to 36 months of follow-up, patients ...

An international team of researchers bioengineering human liver tissues uncovered previously unknown networks of genetic-molecular crosstalk that control the organ's developmental processes – greatly ...

A phase 1 study of miroliverELAP for the treatment of acute liver failure is currently underway;1 first patient in the study underwent the procedure at Intermountain Medical Center in Murray, Utah ...